ivacaftor + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
May 1, 2016 → Aug 1, 2017
NCT ID
NCT02742519About ivacaftor + Placebo
ivacaftor + Placebo is a phase 3 stage product being developed by Vertex Pharmaceuticals for Cystic Fibrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02742519. Target conditions include Cystic Fibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03068312 | Phase 3 | Completed |
| NCT02742519 | Phase 3 | Terminated |
| NCT01614470 | Phase 3 | Completed |
| NCT01614457 | Phase 3 | Completed |
| NCT01262352 | Phase 2 | Completed |
| NCT00953706 | Phase 2 | Terminated |
| NCT00909727 | Phase 3 | Completed |
| NCT00909532 | Phase 3 | Completed |
Competing Products
20 competing products in Cystic Fibrosis